EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer

Amir Karimzadeh, Wencke Lehnert, Daniel Koehler iD, Farzad Shenas, Anna Kisters, Ivayla Apostolova, Susanne Klutmann, Gerhard Adam, Markus Sauer iD

Nuklearmedizin - NuclearMedicine · 01.08.2025 · 64 (04) · 262-271

DOI: 10.1055/a-2654-4048 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.08.2025. Verfasst von Amir Karimzadeh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Dipeptides, Heterocyclic Compounds, 1-Ring, Lutetium. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Theranostics in nuclear oncology combines diagnostic and therapeutic procedures using radiotracers to target tumor cells. Prostate-specific membrane antigen (PSMA) is a key target in metastatic prostate cancer, and the radioligand [177Lu]Lu-PSMA-617, which binds to PSMA, has shown promising results in treating metastatic castration-resistant prostate cancer (mCRPC), leading to its approval by the European Medicines Agency in 2022. In this narrative review, the current evidence of [177Lu]Lu-PSMA-617 in mCRPC was discussed in the context of selected studies and the joint EANM/SNMMI guidelines for Lutetium-177-labeled PSMA-targeted radioligand therapy. The use of [177Lu]Lu-PSMA-617 for post-chemotherapy mCRPC is supported by substantial evidence from the phase II TheraP and the phase III VISION trials, demonstrating its safety and efficacy. The theranostic approach identifies patients likely to benefit from [177Lu]Lu-PSMA-617, which is effective only in tumors with sufficient PSMA expression, as detected by PSMA-ligand PET/CT, which is also used for response assessment. The success of [177Lu]Lu-PSMA-617 in post-chemotherapy mCRPC patients has led to further ongoing studies evaluating its use earlier in the treatment sequence, prior to chemotherapy. To ensure beneficial treatment outcome, adequate patient selection and evaluation of imaging-based response through PSMA-ligand PET/CT is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantDipeptidesHeterocyclic Compounds, 1-RingLutetiumGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleRadioisotopesRadiopharmaceuticalsProspective StudiesNeoplasm MetastasisProstate-Specific Antigen

Substanzen

DipeptidesHeterocyclic Compounds, 1-RingLutetiumGlutamate Carboxypeptidase IIAntigens, SurfaceLutetium-177RadioisotopesPSMA-617FOLH1 protein, humanRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

ORCID-Profile: Daniel Koehler, Markus Sauer

Zitieren

APA

Karimzadeh, A., Lehnert, W., Koehler, D., Shenas, F., Kisters, A., Apostolova, I., Klutmann, S., Adam, G., & Sauer, M. (2025). Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Nuklearmedizin - NuclearMedicine, 64(04), 262-271. https://doi.org/10.1055/a-2654-4048

Vancouver

Karimzadeh A, Lehnert W, Koehler D, Shenas F, Kisters A, Apostolova I, et al. Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Nuklearmedizin - NuclearMedicine. 2025;64(04):262-271. doi:10.1055/a-2654-4048

BibTeX
@article{Karimzadeh2025,
  author = {Karimzadeh, Amir and Lehnert, Wencke and Koehler, Daniel and Shenas, Farzad and Kisters, Anna and Apostolova, Ivayla and Klutmann, Susanne and Adam, Gerhard and Sauer, Markus},
  title = {Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2025},
  volume = {64},
  number = {04},
  pages = {262--271},
  doi = {10.1055/a-2654-4048}
}
Kostenlos starten →